Arch Therapeutics Inc (ARTH): Price and Financial Metrics


Arch Therapeutics Inc (ARTH): $0.10

0.00 (0.00%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

ARTH Stock Price Chart Interactive Chart >

Price chart for ARTH

ARTH Price/Volume Stats

Current price $0.10 52-week high $0.23
Prev. close $0.10 52-week low $0.09
Day low $0.10 Volume 823,900
Day high $0.11 Avg. volume 413,283
50-day MA $0.12 Dividend yield N/A
200-day MA $0.15 Market Cap 23.67M

Arch Therapeutics Inc (ARTH) Company Bio


Arch Therapeutics, Inc. operates as a life science medical device company. The company develops products based on its technology to stop bleeding and control leaking, as well as provides other advantages during surgery and trauma care. Its primary product candidate is AC5 Devices, a biocompatible synthetic peptide that comprises naturally occurring amino acids to achieve hemostasis in minimally invasive and open surgical procedures. The company was founded in 2006 and is based in Framingham, Massachusetts.


ARTH Latest News Stream


Event/Time News Detail
Loading, please wait...

ARTH Latest Social Stream


Loading social stream, please wait...

View Full ARTH Social Stream

Latest ARTH News From Around the Web

Below are the latest news stories about Arch Therapeutics Inc that investors may wish to consider to help them evaluate ARTH as an investment opportunity.

Arch Therapeutics to Present at the LD Micro Invitational XI, June 8 - 10, 2021

FRAMINGHAM, Mass., June 02, 2021 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) (“Arch” or the “Company”), developer of novel self-assembling wound care and biosurgical devices, today announced that it will be presented virtually at the upcoming LD Micro Invitational XI event. Chief Executive Officer, Terrence W. Norchi, MD, and Chief Financial Officer, Mike Abrams, are scheduled to present via webcast, which will be available on-demand as of 4:15 PM ET, Thursday, Jun. 10, 2021. You m

Yahoo | June 2, 2021

Arch Therapeutics’ AC5® Advanced Wound System Presents with Recognition at the 2021 Symposium on Advanced Wound Care (SAWC) Spring | Wound Healing Society (WHS)

Honors for Highest Scoring Poster Abstract in Case Series/Study Category Confirms Commercialization Opportunities for AC5® Advanced Wound SystemFRAMINGHAM, Mass., May 10, 2021 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) (“Arch” or the “Company”), developer of novel self-assembling wound care and biosurgical devices, presents two clinical case reports supporting the broad potential of AC5® Advanced Wound System in chronic and non-healing wounds at the 2021 Symposium on Advanced Wound Care (SAWC) Spring this week. Both abstracts are available as Poster Presentations, and one abstract qualified for Podium Presentation in the Rapid Fire Symposium and earned a ribbon designation in the Poster Hall as the 2021 Highest Scoring Poster Abstract in the “Case Series/Study” category. ...

Yahoo | May 10, 2021

Arch Therapeutics Appoints Michael S. Abrams its Chief Financial Officer

Company Prepares for Next Stage of GrowthFRAMINGHAM, Mass., May 03, 2021 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) (“Arch” or the “Company”), developer of novel self-assembling wound care and biosurgical devices, today announced that it has appointed Michael S. Abrams its Chief Financial Officer effective May 10, 2021. In alignment with the Company’s succession plan, Mr. Abrams joins Arch’s financial team today, one week before assuming the role currently held by the Company’s Chief Financial Officer, Richard Davis. Mr. Davis will remain with the Company during a Transition Period, which will end on June 30, 2021, after which he will support the Company in a consulting role through December 31, 2021. Mr. Abrams has over 25 years of experience as a Chief Financial Officer...

Yahoo | May 3, 2021

Arch Therapeutics to Present at the H.C. Wainwright Global Life Sciences Conference, March 9-10, 2021

Management to provide corporate update on Dermal Sciences and BioSurgeryFRAMINGHAM, Mass., March 02, 2021 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), innovator of AC5® Advanced Wound System and other self-assembling Dermal Sciences and BioSurgery devices, announced today that it will be presenting at the H.C. Wainwright Global Life Sciences Conference, which will be held March 9-10, 2021. Chief Executive Officer, Terrence W. Norchi, MD, and Chief Financial Officer, Richard Davis, are scheduled to present via webcast and be available for meetings. The webcast will be available on-demand starting at 7:00 A.M. EST, Tuesday, March 9, 2021. You may access the live webcast by clicking here: webcast. Attendees may find conference information and registe...

Yahoo | March 2, 2021

Arch Therapeutics Announces Closing of $6.9 Million Private Placement

AC5® Advanced Wound System Commercialization Has CommencedFRAMINGHAM, Mass., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) (“Arch” or the “Company”), developer of novel self-assembling wound care and biosurgical devices, today announced it has closed on the previously announced private placement of 43,125,004 shares of its common stock and warrants to purchase up to an aggregate of 32,343,753 shares of common stock, at a combined purchase price of $0.16 per share of common stock and associated warrant in a private placement. The gross proceeds to Arch from the private placement before deducting underwriting commissions and other offering expenses payable by Arch is $6.9 million. H.C. Wainwright & Co. acted as the exclusive placement agent for the offering. The ...

Yahoo | February 18, 2021

Read More 'ARTH' Stories Here

ARTH Price Returns

1-mo -8.00%
3-mo -43.66%
6-mo -36.71%
1-year -49.37%
3-year -77.53%
5-year -75.06%
YTD -33.29%
2020 -39.94%
2019 -52.91%
2018 23.26%
2017 -26.31%
2016 188.86%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7721 seconds.